REG - Oxford Biomedica PLC - Result of AGM

Oxford BioMedicaAnnouncement

29/05/2018 13:25

RNS Number : 5606P
Oxford Biomedica PLC
29 May 2018
 


 
 
 
 
 
 
Oxford BioMedica plc
Annual General Meeting
 
London, UK - 29 May 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, announces today that  all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:
·      Resolution 10: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;
·      Resolution 11: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and
·     Resolution 12: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolutions passed at the 2018 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (24 May 2018) there were 3,285,053,283 1p ordinary shares in issue, each carrying one vote per share.




 
 
Resolution


 
Votes
For


Votes at
Chairman's
Discretion


Votes at
other proxy
Discretion


 
Votes
Against


 
Votes
Withheld


 
Total
votes cast


Result






































Ordinary resolutions


























































1


1,988,588,475


582,120


5,741,189


233,441


85,853


1,995,231,078


Passed






































2


1,982,688,012


657,354


5,741,189


4,411,157


1,733,366


1,995,231,078


Passed






































3


1,923,486,721


811,240


5,741,189


56,288,698


8,903,541


1,995,231,389


Passed




4


 
1,988,021,008


 
669,140


 
5,741,189


 
494,021


 
305,721


 
1,995,231,079


 
Passed






































5


1,988,311,289


655,920


5,741,189


216,678


306,314


1,995,231,390


Passed






































6


1,988,029,653


655,920


5,741,189


622,025


182,292


1,995,231,079


Passed






































7


1,988,368,406


674,159


5,741,189


178,737


268,588


1,995,231,079


Passed






































8


1,988,584,716


657,182


5,741,189


153,238


95,065


1,995,231,390


Passed






































9


1,986,683,108


641,653


5,741,189


767,858


1,397,270


1,995,231,078


Passed






































 
Special resolutions


























































10


1,986,880,927


629,431


5,741,189


1,134,133


845,710


1,995,231,390


Passed






































11


1,986,323,670


624,811


5,741,189


1,687,542


854,177


1,995,231,389


Passed






































12


1,971,075,702


624,811


5,741,189


17,667,961


121,727


1,995,231,390


Passed






































 
- Ends -
 




For further information, please contact:


 




 
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
 


 
Tel: +44 (0)1865 783 000




 
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
 


 
 
Tel: +44 (0)20 3709 5700




 
Notes for editors
 
 
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSEAFEUFASEFI